Inhibitors of human immunodeficiency virus replication

1. A compound of Formula I, or a pharmaceutically acceptable salt thereof:

wherein:

R 0 , R 1 , and R 2 are each independently hydrogen, Cl, F, -OMe, —CN, —C 1 -C 3 alkyl, or —C 3 -C 5 cycloalkyl, wherein —C 1 -C 3 alkyl may be optionally substituted with from 1-3 fluorines;

Q is selected from:

G 1 is hydrogen, C 1 -C 5 alkyl, —SO 2 CH 3 , —CO 2 H, —C(O)NG 12 G 13 -(C 1 -C 3 alkyl)SO 2 CH 3 , —(C 1 -C 3 alkyl)C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)NG 12 G 13 , —(C 1 -C 3 alkyl)CO 2 H, —CCC(CH 3 ) 2 SO 2 CH 3 , —(C 1 -C 3 alkyl)CO 2 H, Cl, or F wherein C 1 -C 3 alkyl or C 1 -C 5 alkyl is optionally substituted with 1-3 fluorines;

G 2 is hydrogen, C 1 -C 5 alkyl, —SO 2 CH 3 , —CO 2 H, —C(O)NG 12 G 13 , —NG 12 G 13 , —(C 1 -C 3 alkyl)SO 2 CH 3 , —(C 1 -C 3 alkyl)C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)NG 12 G 13 , —(C 1 -C 3 alkyl)CO 2 H, —CCC(CH 3 ) 2 SO 2 CH 3 , —(C 1 -C 3 alkyl)CO 2 H, Cl, or F, wherein C 1 -C 3 alkyl or C 1 -C 5 alkyl is optionally substituted with 1-3 fluorines or 1-2 CH 3 groups;

G 3 is hydrogen, —SO 2 CH 3 , benzyl, or C 1 -C 3 alkyl, wherein C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines;

G 4 is hydrogen, C 1 -C 3 alkyl, -benzyl, —SO 2 (C 1 -C 3 alkyl), —(C 2 -C 3 alkyl)SO 2 CH 3 , —C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)C(O)NG 12 G 13 , —(C 2 -C 3 alkyl)C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)CO 2 H, —(C 1 -C 3 alkyl)CO 2 H, wherein C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines;

G 5 is hydrogen, C 1 -C 3 alkyl, —SO 2 (C 1 -C 3 alkyl), —C(O)NG 12 G 13 , CO 2 H, —NG 12 G 13 , or CN wherein C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines or chlorines;

G 6 is hydrogen or methyl wherein methyl is optionally substituted with 1-3 fluorines;

G 7 is hydrogen, or C 1 -C 3 alkyl wherein C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines;

G 8 is hydrogen, C 1 -C 3 alkyl, -benzyl, —SO 2 (C 1 -C 3 alkyl), —(C 2 -C 3 alkyl)SO 2 CH 3 , —C(O)NG 12 G 13 -(C 1 -C 3 alkyl)C(O)NG 12 G 13 , —(C 2 -C 3 alkyl)C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)CO 2 H, —(C 1 -C 3 alkyl)CO 2 H, wherein C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines;

G 9 is hydrogen or methyl wherein methyl is optionally substituted with 1-3 fluorines;

G 10 is hydrogen or methyl wherein methyl is optionally substituted with 1-3 fluorines;

Y is N or C-G 11 ;

G 11 is hydrogen, C 1 -C 3 alkyl, —O(C 1 -C 3 alkyl), —SO 2 CH 3 , —CO 2 H, —NG 12 G 13 , CN, or —C(O)NG 12 G 13 wherein C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines;

Z is hydrogen, —C 1 -C 3 alkyl, —NH 2 , —SO 2 (C 1 -C 3 alkyl), —O(C 1 -C 3 alkyl), —(C 1 -C 3 alkyl)SO 2 CH 3 , —C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)NG 12 G 13 , —CCC(CH 3 ) 2 SO 2 CH 3 , —CCC(CH 3 ) 2 OH, —(C 1 -C 3 alkyl)COOH, —CCC(CH 3 ) 2 C(O)NG 12 G 13 , —CCC(CH 3 ) 2 COOH, —CCC(CH 3 ) 3 , —CCC(CH 3 ) 2 OC 1 -C 3 alkyl, wherein —C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines;

G 12 and G 13 are each independently hydrogen or C 1 -C 3 alkyl;

A is N or C-G 14 ;

E is N or C-G 14 ;

F is N or C-G 15 ;

G is N, C-G 16 ;

with the proviso that no more than two of A, E, F, or G may be N;

G 14 is hydrogen, —C 1 -C 5 alkyl, —C 3 -C 6 cycloalkyl, —SO 2 CH 3 , —CO 2 H, —CO 2 Me, —C(O)NG 12 G 13 , —NG 12 G 13 , —(C 1 -C 3 alkyl)SO 2 CH 3 , —(C 1 -C 3 alkyl)C(O)NG 12 G 13 , —(C 1 -C 3 alkyl)NG 12 G 13 , —(C 1 -C 3 alkyl)CO 2 H, —CCC(CH 3 ) 2 SO 2 CH 3 , —(C 1 -C 3 alkyl)C 2 H, Cl, F, Br, —CN, or —O—C 1 -C 5 alkyl, wherein C 1 -C 5 alkyl, —O—C 1 -C 5 alkyl, or —C 3 -C 6 cycloalkyl is optionally substituted with 1-3 fluorines;

G 15 is hydrogen, C 1 -C 5 alkyl, —C 3 -C 5 cycloalkyl, —SO 2 CH 3 , —CO 2 H, —CO 2 Me, —C(O)NG 12 G 13 , —NG 12 G 13 , CN, Cl, F, Br, —O—C 1 -C 5 alkyl, wherein C 1 -C 5 alkyl, C 1 -C 5 cycloalkyl or —O—C 1 -C 5 alkyl is optionally substituted with 1-3 fluorines;

G 16 is hydrogen, —C 1 -C 5 alkyl, —NH 2 , Cl, F, Br, —CN, or —O—C 1 -C 5 alkyl, wherein C 1 -C 5 alkyl or —O—C 1 -C 5 alkyl, is optionally substituted with 1-3 fluorines;

X is

R=X;

R 3 is hydrogen, Cl, F, -OMe, —CN, —C 1 -C 3 alkyl, or —C 3 -C 5 cycloalkyl, wherein —C 1 -C 3 alkyl may be optionally substituted with from 1-3 fluorines;

R 4 is hydrogen, C 1 -C 3 alkyl, or —SO 2 CH 3 wherein C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines;

R 5 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or NG 12 , G 13 ;

R 6 and R 7 are each independently hydrogen, chlorine, fluorine, —OC 1 -C 3 alkyl, —CN, —CO 2 H, —CONG 12 G 13 , —NG 12 G 13 , —NHCOR 8 , or —CONHSO 2 R 9 or —NHSO 2 R 9 wherein —C 1 -C 3 alkyl, —OC 1 -C 3 alkyl, or —C 3 -C 5 cycloalkyl is optionally substituted with 1-3 fluorines;

R 8 is —C 1 -C 3 alkyl;

R 9 is —C 1 -C 6 alkyl, —C 3 -C 5 cycloalkyl or NG 12 , G 13 wherein —C 3 -C 5 cycloalkyl is optionally substituted with a methyl group;

R 10 is hydrogen, chlorine, fluorine, —C 1 -C 3 alkyl, —OC 1 -C 3 alkyl, —C 3 -C 5 cycloalkyl, —CN, —CO 2 H, —SO 2 C 1 -C 3 alkyl, —SO 2 NR a R b , —CONG 12 G 13 , —NG 12 G 13 , —NHCOR 8 , or —CONHSO 2 R 9 or —NHSO 2 R 9 wherein —C 1 -C 3 alkyl, —OC 1 -C 3 alkyl, or —C 3 -C 5 cycloalkyl is optionally substituted with 1-3 fluorines;

R a and R b are independently H, —C 1 -C 3 alkyl, or together with the N to which they are attached form a morpholine, azetidine, pyrrolidine, piperidine, piperazine, or N-Me piperazine;

R 11 is hydrogen, —C 1 -C 3 alkyl, C 3 -C 5 cycloalkyl —OC 1 -C 3 alkyl, —CONG 12 G 13 , —NG 12 G 13 , —NHCOR 8 , —CONHSO 2 R 9 or —NHSO 2 R 9 wherein —C 1 -C 3 alkyl, —OC 1 -C 3 alkyl, or —C 3 -C 5 cycloalkyl is optionally substituted with 1-3 Fluorines;

R 12 is -hydrogen or methyl;

R 13 is —C 1 -C 3 alkyl or —C 3 -C 6 cycloalkyl wherein —C 1 -C 3 alkyl is optionally substituted with 1-3 fluorines; and

W is selected from:

wherein R 14 is —NHSO 2 CH 3 , —C 1 -C 3 alkyl, —C 3 -C 6 cycloalkyl, —OH, —F, Cl, Br, or methyl, wherein methyl is optionally substituted with 1-3 fluorines.

2. A compound or salt according to claim 1 wherein said compound or salt is a compound of Formula II, or a pharmaceutically acceptable salt thereof:

wherein Q and W are as defined in claim 1 ; and

R 1 and R 2 are each independently hydrogen or F.

3. A compound or salt according to claim 2 , wherein the stereochemistry of the carbon to which Q is bonded is as depicted below in Formula III:

4. A compound or salt according to claim 3 wherein R 1 and R 2 are each F.

5. A compound or salt of claim 1 , selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

6. A pharmaceutical composition comprising a compound or salt according to claim 1 and further comprising a pharmaceutically acceptable carrier, excipient, and/or diluent.

7. A method of treating HIV infection comprising administering a composition according to claim 6 to a patient.

8. The method of claim 7 wherein said administration is oral.

9. The method of claim 8 wherein said administration comprises administering by injection or subcutaneously to a patient to achieve a long acting effect which would require an infrequent dosing interval.

10. The method of claim 7 wherein said method further comprises administration of at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

11. The method of claim 10 wherein said at least one other agent is selected from the group consisting of FTC, ibalizumab, PRO-140, dolutegravir, abacavir lamivudine, fosamprenavir, rilpivirine, atazanavir, darunavir, MK-8718, MK-8591, tenofovir alfenamide, and bictegravir.